26
Participants
Start Date
October 31, 2008
Primary Completion Date
April 30, 2010
Study Completion Date
April 30, 2010
CP-4126
Step 1: Dose escalation oral CP-4126 until maximum tolerated dose. Step 2: Oral CP-4126 day 1 and 15 + IV Gemcitabine 1000 mg/m2 day 8 in a 4 week schedule until complete response or disease worsening / progression
Gemcitabine
Step 1: Dose escalation oral CP-4126 until maximum tolerated dose Step 2: Oral CP-4126 day 8 and 15 + IV Gemcitabine 1000 mg/m2 day 1 in a 4 week schedule until complete response or disease worsening / progression
Institute Jules Bordet, Brussels
The Netherlands Cancer Institute, Amsterdam
University Medical Centre Utrecht, Utrecht
Lead Sponsor
Clavis Pharma
INDUSTRY